CERVICAL ADENOCARCINOMA
Clinical trials for CERVICAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare cervical cancer: Triple-Drug trial launches
Disease control Recruiting nowThis study tests a combination of three drugs (IN10018, nab-paclitaxel, and cadonilimab) in women with a rare, hard-to-treat type of cervical cancer that has spread or come back. The goal is to see if this treatment can shrink tumors or slow the disease. About 25 adult women who …
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
Could a shorter radiation course be just as effective for cervical cancer?
Disease control Recruiting nowThis study compares a shorter, higher-dose radiation schedule (hypofractionated) to the standard longer schedule for women with locally advanced cervical cancer. All participants also receive chemotherapy and internal radiation. The goal is to see if the shorter schedule is as sa…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Uganda Cancer Institute • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
Targeted radiation zaps Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug that delivers radiation directly to cancer cells. It is for people with advanced solid tumors like bladder, breast, lung, or cervical cancer that have not responded to prior treatments. The main goals are to find the safest dose and see if …
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New drug targets tumors directly in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in about 144 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors to kill cancer cells while limiting…
Matched conditions: CERVICAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated May 06, 2026 16:03 UTC